NCT06103617View on ClinicalTrials.gov

Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

June 1, 2025

Conditions
Head and Neck CancerRecurrent Cancer
Interventions
DRUG

Penicillamine

Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.

Trial Locations (2)

510515

RECRUITING

Southern medical university, Guangzhou

Unknown

RECRUITING

Nanfang Hospital, Sourthern Medical University, Guangzhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER